• Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Biogen Idec Inc

+ Add to Watchlist

BIIB:US

342.680 USD 0.360 0.10%

As of 20:10:00 ET on 09/02/2014.

Snapshot for Biogen Idec Inc (BIIB)

Open: 345.470 Day's Range: 340.600 - 347.789 Volume: 715,592
Previous Close: 343.040 52wk Range: 213.050 - 358.890 1-Yr Rtn: +54.51%

Stock Chart for BIIB

No chart data available.
  • BIIB:US 342.680
  • 1D
  • 1M
  • 1Y
343.040
Interactive BIIB Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BIIB

Current P/E Ratio (ttm) 37.7845
Estimated P/E(12/2014) 26.1588
Relative P/E vs. SPX 2.1005
Earnings Per Share (USD) (ttm) 9.0693
Est. EPS (USD) (12/2014) 13.1000
Est. PEG Ratio 1.3665
Market Cap (M USD) 80,922.07
Shares Outstanding (M) 236.14
30 Day Average Volume 1,147,346
Price/Book (mrq) 8.4635
Price/Sale (ttm) 9.7198
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 10/28/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BIIB

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for BIIB

Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.

George A ScangosChief Executive OfficerSusan H AlexanderExec VP/Chief Legal Ofcr/Secy
Paul J ClancyExec VP:Finance/CFOStephen H Holtzman "Steve"Exec VP:Corporate Development
More Company Profile & Key Executives for BIIB

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil